Ad26.ZEBOV

BIOLOGICAL15 trials

Conditions

EbolaEbola Viral DiseaseEbola Virus DiseaseHealthyHemorrhagic Fever, EbolaHiv

Phase 1

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

CompletedNCT02376400

Crucell Holland BVHealthy

Start: 2015-04-30End: 2016-09-30Updated: 2016-12-08

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

CompletedNCT02376426

Crucell Holland BVHealthy

Start: 2015-03-31End: 2016-06-30Updated: 2016-12-08

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

CompletedNCT02495246

University of OxfordEbola Virus Disease

Start: 2015-09-21End: 2017-08-22Updated: 2018-04-11

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

CompletedNCT02860650

Janssen Vaccines & Prevention B.V.Healthy

Start: 2016-08-31End: 2018-01-31Updated: 2018-02-05

Phase 2

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

CompletedNCT02416453

Janssen Vaccines & Prevention B.V.Ebola Viral Disease

Start: 2015-06-15End: 2018-01-19Updated: 2021-02-08

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

CompletedNCT02564523

Janssen Vaccines & Prevention B.V.Hemorrhagic Fever, Ebola

Start: 2015-11-06End: 2019-02-12Updated: 2022-03-07

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

CompletedNCT02598388

Janssen Vaccines & Prevention B.V.Hemorrhagic Fever, Ebola

Start: 2015-12-10End: 2018-12-12Updated: 2025-02-04

Partnership for Research on Ebola VACcinations

CompletedNCT02876328

National Institute of Allergy and Infectious Diseases (NIAID)Ebola Virus Disease

Start: 2017-03-27End: 2023-12-20Updated: 2024-06-26

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

CompletedNCT03929757

Janssen Vaccines & Prevention B.V.Ebola Virus Disease

Start: 2019-08-19End: 2022-09-28Updated: 2025-05-25

An open label, phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen

Active, not recruitingPACTR202102747294430

London School of Hygiene and Tropical MedicineEbola

Start: 2021-03-15Target: 50Updated: 2026-01-27

Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)

CompletedNCT05064956

London School of Hygiene and Tropical MedicineEbola, Ebola Virus Disease, Hiv

Start: 2021-10-06End: 2022-10-24Updated: 2023-02-21

Phase 3

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

CompletedNCT02509494

Janssen Vaccines & Prevention B.V.Ebola Virus Disease

Start: 2015-09-30End: 2019-07-03Updated: 2022-07-18

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

TerminatedNCT02661464

Janssen Vaccines & Prevention B.V.Hemorrhagic Fever, Ebola

Start: 2016-05-31End: 2021-12-13Updated: 2024-01-02

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

CompletedNCT04228783

Janssen Vaccines & Prevention B.V.Ebola

Start: 2020-02-18End: 2022-04-25Updated: 2025-05-25

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

CompletedNCT04556526

Janssen Vaccines & Prevention B.V.Healthy

Start: 2020-10-05End: 2023-03-02Updated: 2025-02-03

PLoS neglected tropical diseases2026-01-30

Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial

Nature Medicine2025-09-083 citations

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Emerging Microbes & Infections2024-11-192 citations

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.

2024-09-038 citations

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial

The Journal of Infectious Diseases2024-07-121 citations

Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial

Vaccines2024-05-043 citations

Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without Human Immunodeficiency Virus in Africa

Clinical Infectious Diseases2024-04-213 citations

Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

PLoS neglected tropical diseases2024-04-111 citations

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

Human Vaccines & Immunotherapeutics2024-03-246 citations

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study

Vaccines2024-02-176 citations

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.

2023-11-183 citations

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Clinical Infectious Diseases2023-11-1314 citations

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.

2023-11-017 citations

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen

Vaccines2023-08-024 citations

Randomized Trial of Vaccines for Zaire Ebola Virus Disease

New England Journal of Medicine2022-12-1468 citations

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.

2022-11-3014 citations

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

PLoS ONE2022-10-0531 citations

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

Trials2022-06-2015 citations

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

PLoS Medicine2022-01-1159 citations

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.

2021-12-207 citations

9 more papers not shown

Ad26.ZEBOV

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers